Criticism for Spahn's plan to ban discounts for mail-order pharmaciesSZ on Friday (p4) criticises Health Minister Jens Spahn's proposal to ban discounts for mail-order pharmacies by maintaining a fixed price for prescription drugs (APMHE 62329), saying he "serves the German pharmacists' lobby instead of fulfilling his task as a minister".
Merck KGaA invests €1 billion in DarmstadtMerck will invest €1 billion in its headquarters in Darmstadt, Germany until 2025, to "secure the future viability of company headquarters as a central science and technology hub" reported FAZ on Thursday (p18) (APMHE 62335).
Stada invests in manufacturing and recruits abroadGeneric drug maker Stada plans to invest a single-digit million euros sum in manufacturing and to hire a few hundred employees worldwide in 2019, reported FAZ on Wednesday (p38)
Biogen's shares slump 27% on Alzheimer's flopBiogen's shares on Thursday lost 27% after the announcement of the failure of two Phase III trials on aducanumab in Alzheimer's disease, reports FAZ on Friday (p19) (APMHE 62348).
Access to Gilead's Sovaldi obstructed by high therapy costsHigh therapy costs for hepatitis C virus (HCV) drug Sovaldi (sofosbuvir) are obstructing access worldwide, leading Doctors without Borders and 37 other organisations to challenge Gilead's patent in court, Die Welt reported on Monday (p20).
Rani Therapeutics develops 'robotic biologic pill'U.S. start-up Rani Therapeutics is developing RaniPill, a "robotic biologic pill" designed to replace injections of biologics, reports weekly Wirtschaftswoche on Friday (p72-73).
Euronext offers biotech start-ups training for IPOEuronext organised a free "IPO training" for biotech and medical technology companies, reported Handelsblatt on Tuesday (p20-21).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.